Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Rina Plattner, PhD

Cancer Center Member

Co-Leader, Molecular and Cellular Oncology Program

rina plattner

Research Programs:
Molecular and Cellular Oncology

Colleges & Departments:
College of Medicine, Department of Pharmacology and Nutritional Sciences

Faculty Rank:

Research Focus

Abl non-receptor tyrosine kinases, cancer invasion.

Contact Information

209 Combs Building
University of Kentucky
Lexington, KY 40536
United States



  1. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Cibull ML, Wang Ch, Novak M, Kaetzel, DM, Plattner R. Oncogene 31:1804-1816, 2012.
  2. Deregulated abl kinases promote proliferation, anchorage-independent growth and survival of aggressive breast cancer cells. Srinivasan D, Sims JT, Plattner R. Oncogene 27:1095-1105, 2008.
  3. SHP-2 is a novel target of Abl kinases during cell proliferation. Mitra S, Beach C, Feng GS, Plattner R. J Cell Sci 121:3335-3346, 2008.
  4. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κΒ and HSP27/p38/AKT pathways and by inhibiting ABCB1. Sims JT, Ganguly SS, Bennett H, Friend WJ, Tepe J, Plattner R. PLoS One 2013.


Research Equipment